

【 Press release 】



ESSEX BIO-TECHNOLOGY LIMITED **億勝生物科技有限公司**

(Stock Code: 1061)

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

Hong Kong, 22 January 2026

Essex Bio-Technology Limited (“**EssexBio**” or the “**Group**”, Stock Code: 1061.HK) is pleased to announce its participation in the **Asia-Pacific Academy of Ophthalmology Congress (“APAO”) 2026**, to be held from **5 to 8 February 2026** at the **Hong Kong Convention and Exhibition Centre**. This marks the Group’s second year of participation at APAO, reaffirming its continued commitment to the regional ophthalmology community.

During the congress, EssexBio will host a dedicated booth showcasing key products and pipeline assets from its ophthalmology portfolio, and to engage with ophthalmologists, healthcare professionals, and industry partners across Asia-Pacific.

At APAO 2026, the Group will highlight two key products:

1. EB12-20145P (Bevacizumab)

EB12-20145P continues to demonstrate strong clinical development momentum. This programme has been selected for a poster session, providing an opportunity to present clinical progress and development insights to the international ophthalmology community.

Poster Session Details: <https://2026.apaophth.org/program-schedule/?code=0464>

2. BFS Beifushu® Eye Drops

EssexBio has achieved a significant milestone with BFS Beifushu® now commercially available in Singapore, starting with the Singapore National Eye Centre (SNEC), one of the region's leading tertiary eye care institutions, with plans to pursue additional healthcare institutions and expand across APAC, subject to local regulatory and commercial considerations.

The Group's presence at APAO 2026, together with the advancing clinical development of EB12-20145P and the APAC rollout of BFS Beifushu®, underscores EssexBio's dedication to advancing ophthalmic care through **clinically proven, first-in-class and best-in-class therapeutic solutions**, while strengthening collaboration with leading eye care institutions and professionals across the region.

Visitors are invited to **visit the EssexBio booth** to learn more about the Group's ophthalmic solutions, clinical applications, and regional development strategy.

~ End ~

About EssexBio (1061.HK)

EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun(適麗順®) (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,100 hospitals, supported by the Company's 46 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Media Enquiry:

Strategic Financial Relations Limited (Website: <http://www.sprg.com.hk>)

Shelly Cheng +852 2864 4857 shelly.cheng@sprg.com.hk

Angela Shen +852 2864 4870 angela.shen@sprg.com.hk

Media: media@essex.com.cn

Investor Enquiry:

Investor Relations: investors@essex.com.cn